Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC.CRL · Entity 3398 | EVP, Corp Strategy & Develop | August 10, 2026 | August 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Report date August 10, 2026 · Filed August 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 31,041 |
Reported balance
After 2026-08-10 transaction · row 1
1 source rowRow 1 · 2026-08-10 · Gift · Disposed 257 · Balance 31,041 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 22, 2023 Filed Feb 22, 2023 21:24 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 317 | $243.60 | $77,221.20 |
DisclosureSEC source: 0001127602-23-006461 · form4.xml · nonDerivative · entry 1 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,330 Read SEC document |
| January 27, 2023 Filed Jan 30, 2023 21:39 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 3,261 | $244.29 | $796,629.69 |
DisclosureSEC source: 0001127602-23-002668 · form4.xml · nonDerivative · entry 2 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,647 Read SEC document |
| January 27, 2023 Filed Jan 30, 2023 21:39 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 8,676 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-002668 · form4.xml · nonDerivative · entry 1 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,908 F1 · shares: Reflects shares of common stock issued following the achievement of performance goals set forth in performance share unit awards originally granted on May 29, 2020. Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 21:55 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionStock Options (Right to Buy) · Derivative | 6,409 | $0.00 Strike: $109.34 | $0.00 |
DisclosureSEC source: 0001127602-22-026898 · form4.xml · derivative · entry 5 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,409 shares Expires 2023-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 21:55 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 1,106 | $224.85 | $248,684.32 |
DisclosureSEC source: 0001127602-22-026898 · form4.xml · nonDerivative · entry 4 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,232 F3 · price: This transaction was executed in multiple trades at prices ranging from $224.66 to $225.16. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 21:55 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 4,165 | $224.41 | $934,683.89 |
DisclosureSEC source: 0001127602-22-026898 · form4.xml · nonDerivative · entry 3 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,338 F2 · price: This transaction was executed in multiple trades at prices ranging from $223.68 to $224.63. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 21:55 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 1,138 | $223.06 | $253,836.59 |
DisclosureSEC source: 0001127602-22-026898 · form4.xml · nonDerivative · entry 2 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,503 F1 · price: This transaction was executed in multiple trades at prices ranging from $222.66 to $223.37. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 21:55 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionCommon Stock | 6,409 | $109.34 | $700,760.06 |
DisclosureSEC source: 0001127602-22-026898 · form4.xml · nonDerivative · entry 1 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,641 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 04, 2022 Filed Nov 7, 2022 23:54 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 534 | $216.36 | $115,536.24 |
DisclosureSEC source: 0001127602-22-025053 · form4.xml · nonDerivative · entry 1 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,232 Read SEC document |
| August 05, 2022 Filed Aug 8, 2022 19:03 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 200 | $226.13 | $45,226.82 |
DisclosureSEC source: 0001127602-22-020666 · form4.xml · nonDerivative · entry 2 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,766 Read SEC document |
| July 06, 2022 Filed Aug 8, 2022 19:03 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GiftCommon Stock | 195 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-020666 · form4.xml · nonDerivative · entry 1 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,966 Read SEC document |
| May 29, 2022 Filed May 31, 2022 23:09 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 223 | $244.41 | $54,503.43 |
DisclosureSEC source: 0001127602-22-016066 · form4.xml · nonDerivative · entry 3 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,161 Read SEC document |
| May 28, 2022 Filed May 31, 2022 23:09 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 125 | $244.41 | $30,551.25 |
DisclosureSEC source: 0001127602-22-016066 · form4.xml · nonDerivative · entry 2 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,384 Read SEC document |
| May 27, 2022 Filed May 31, 2022 23:09 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantStock Options (Right to Buy) · Derivative | 4,478 | $244.41 Strike: $244.41 | $1,094,467.98 |
DisclosureSEC source: 0001127602-22-016066 · form4.xml · derivative · entry 4 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,478 Underlying: Common Stock · 4,478 shares Expires 2032-05-27 F2 · shares: Stock Options vest as follows: 1,119 on May 27, 2023, 1,120 on May 27, 2024, 1,119 on May 27, 2025 and 1,120 on May 27, 2026. Read SEC document |
| May 27, 2022 Filed May 31, 2022 23:09 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 1,657 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-016066 · form4.xml · nonDerivative · entry 1 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,509 F1 · shares: Unvested restricted stock units vest as follows: 414 on May 27, 2023, 414 on May 27, 2024, 414 on May 27, 2025 and 415 on May 27, 2026. Read SEC document |
| February 23, 2022 Filed Feb 23, 2022 21:44 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 315 | $289.58 | $91,217.70 |
DisclosureSEC source: 0001127602-22-006343 · form4.xml · nonDerivative · entry 7 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,247 Read SEC document |
| February 23, 2022 Filed Feb 24, 2022 23:37 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 395 | $292.75 | $115,636.25 |
DisclosureSEC source: 0001127602-22-006657 · form4.xml · nonDerivative · entry 1 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,852 Read SEC document |
| February 22, 2022 Filed Feb 23, 2022 21:44 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 392 | $290.83 | $114,006.93 |
DisclosureSEC source: 0001127602-22-006343 · form4.xml · nonDerivative · entry 6 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,562 Read SEC document |
| February 22, 2022 Filed Feb 23, 2022 21:44 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 4 | $290.81 | $1,163.24 |
DisclosureSEC source: 0001127602-22-006343 · form4.xml · nonDerivative · entry 5 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,954 Read SEC document |
| February 22, 2022 Filed Feb 23, 2022 21:44 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 317 | $293.61 | $93,074.37 |
DisclosureSEC source: 0001127602-22-006343 · form4.xml · nonDerivative · entry 4 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,958 Read SEC document |
| February 18, 2022 Filed Feb 23, 2022 21:44 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionStock Options (Right to Buy) · Derivative | 743 | $0.00 Strike: $88.05 | $0.00 |
DisclosureSEC source: 0001127602-22-006343 · form4.xml · derivative · entry 8 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 743 shares Expires 2022-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 18, 2022 Filed Feb 23, 2022 21:44 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 1,143 | $291.80 | $333,527.40 |
DisclosureSEC source: 0001127602-22-006343 · form4.xml · nonDerivative · entry 3 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,275 F1 · price: This transaction was executed in multiple trades at prices ranging from $291.68 to $292.02. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 18, 2022 Filed Feb 23, 2022 21:44 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionCommon Stock | 743 | $88.05 | $65,421.15 |
DisclosureSEC source: 0001127602-22-006343 · form4.xml · nonDerivative · entry 2 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,418 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2022 Filed Feb 23, 2022 21:44 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GiftCommon Stock | 150 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-006343 · form4.xml · nonDerivative · entry 1 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,675 Read SEC document |
| January 28, 2022 Filed Feb 1, 2022 22:39 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 4,570 | $312.24 | $1,426,936.80 |
DisclosureSEC source: 0001127602-22-002801 · form4.xml · nonDerivative · entry 2 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,825 Read SEC document |
| January 28, 2022 Filed Feb 1, 2022 22:39 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 11,344 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-002801 · form4.xml · nonDerivative · entry 1 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,395 F1 · shares: Reflects shares of common stock issued following the achievement of performance goals set forth in performance share unit awards originally granted on February 22, 2019. Read SEC document |
| December 25, 2021 Filed Dec 27, 2021 20:43 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 6,771 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-031913 · form4.xml · nonDerivative · entry 2 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,051 F1 · shares: Unvested restricted stock units vest as follows: 6,771 on December 25, 2026. Read SEC document |
| November 22, 2021 Filed Dec 27, 2021 20:43 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GiftCommon Stock | 182 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-031913 · form4.xml · nonDerivative · entry 1 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,280 Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 15:56 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 300 | $409.40 | $122,820.00 |
DisclosureSEC source: 0001127602-21-023433 · form4.xml · nonDerivative · entry 4 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,462 F4 · price: This transaction was executed in multiple trades at prices ranging from $409.10 to $409.58. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 15:56 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 1,042 | $402.43 | $419,335.19 |
DisclosureSEC source: 0001127602-21-023433 · form4.xml · nonDerivative · entry 3 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,762 F3 · price: This transaction was executed in multiple trades at prices ranging from $402.25 to $402.58. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 15:56 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 900 | $401.66 | $361,497.60 |
DisclosureSEC source: 0001127602-21-023433 · form4.xml · nonDerivative · entry 2 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,804 F2 · price: This transaction was executed in multiple trades at prices ranging from $401.48 to $401.85. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 15:56 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 1,458 | $400.91 | $584,522.41 |
DisclosureSEC source: 0001127602-21-023433 · form4.xml · nonDerivative · entry 1 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,704 F1 · price: This transaction was executed in multiple trades at prices ranging from $400.22 to $401.19. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 29, 2021 Filed Jun 1, 2021 22:03 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 223 | $337.99 | $75,371.77 |
DisclosureSEC source: 0001127602-21-018567 · form4.xml · nonDerivative · entry 2 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,162 Read SEC document |
| May 28, 2021 Filed Jun 1, 2021 22:03 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantStock Options (Right to Buy) · Derivative | 3,476 | $337.99 Strike: $337.99 | $1,174,853.24 |
DisclosureSEC source: 0001127602-21-018567 · form4.xml · derivative · entry 3 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,476 Underlying: Common Stock · 3,476 shares Expires 2031-05-28 F2 · shares: Stock Options vest as follows: 869 on May 28, 2022, 869 on May 28, 2023, 869 on May 28, 2024 and 869 on May 28, 2025. Read SEC document |
| May 28, 2021 Filed Jun 1, 2021 22:03 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 1,124 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-018567 · form4.xml · nonDerivative · entry 1 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,385 F1 · shares: Unvested restricted stock units vest as follows: 281 on May 28, 2022, 281 on May 28, 2023, 281 on May 28, 2024 and 281 on May 28, 2025. Read SEC document |
| February 25, 2021 Filed Feb 26, 2021 21:51 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionStock Options (Right to Buy) · Derivative | 2,750 | $0.00 Strike: $88.05 | $0.00 |
DisclosureSEC source: 0001127602-21-008123 · form4.xml · derivative · entry 6 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 743 Underlying: Common Stock · 2,750 shares Expires 2022-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 25, 2021 Filed Feb 26, 2021 21:51 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 1,422 | $283.50 | $403,143.54 |
DisclosureSEC source: 0001127602-21-008123 · form4.xml · nonDerivative · entry 5 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,261 F4 · price: This transaction was executed in multiple trades at prices ranging from $283.195 to $283.945. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 25, 2021 Filed Feb 26, 2021 21:51 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 967 | $282.27 | $272,951.13 |
DisclosureSEC source: 0001127602-21-008123 · form4.xml · nonDerivative · entry 4 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,683 F3 · price: This transaction was executed in multiple trades at prices ranging from $282.01 to $282.89. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 25, 2021 Filed Feb 26, 2021 21:51 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 4,334 | $281.41 | $1,219,643.08 |
DisclosureSEC source: 0001127602-21-008123 · form4.xml · nonDerivative · entry 3 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,650 F2 · price: This transaction was executed in multiple trades at prices ranging from $281.01 to $282.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 25, 2021 Filed Feb 26, 2021 21:51 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 2,012 | $280.75 | $564,877.25 |
DisclosureSEC source: 0001127602-21-008123 · form4.xml · nonDerivative · entry 2 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,984 F1 · price: This transaction was executed in multiple trades at prices ranging from $280.01 to $281.005. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 25, 2021 Filed Feb 26, 2021 21:51 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionCommon Stock | 2,750 | $88.05 | $242,137.50 |
DisclosureSEC source: 0001127602-21-008123 · form4.xml · nonDerivative · entry 1 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,996 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 24, 2021 Filed Feb 25, 2021 20:27 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 322 | $282.98 | $91,119.56 |
DisclosureSEC source: 0001127602-21-007876 · form4.xml · nonDerivative · entry 1 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,246 Read SEC document |
| February 23, 2021 Filed Feb 24, 2021 15:42 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 315 | $283.59 | $89,330.85 |
DisclosureSEC source: 0001127602-21-007517 · form4.xml · nonDerivative · entry 2 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,568 Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 15:42 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 317 | $289.55 | $91,787.35 |
DisclosureSEC source: 0001127602-21-007517 · form4.xml · nonDerivative · entry 1 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,883 Read SEC document |
| January 29, 2021 Filed Feb 2, 2021 16:46 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 4,708 | $260.88 | $1,228,223.04 |
DisclosureSEC source: 0001127602-21-003434 · form4.xml · nonDerivative · entry 3 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,200 Read SEC document |
| January 29, 2021 Filed Feb 2, 2021 16:46 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 11,862 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-003434 · form4.xml · nonDerivative · entry 2 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,908 F1 · shares: Reflects shares of common stock issued following the achievement of performance goals set forth in performance share unit awards originally granted on February 23, 2018. Read SEC document |
| December 01, 2020 Filed Feb 2, 2021 16:46 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GiftCommon Stock | 310 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-003434 · form4.xml · nonDerivative · entry 1 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,046 Read SEC document |
| November 04, 2020 Filed Nov 5, 2020 16:46 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionStock Options (Right to Buy) · Derivative | 3,042 | $0.00 Strike: $144.67 | $0.00 |
DisclosureSEC source: 0001127602-20-028214 · form4.xml · derivative · entry 10 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,128 Underlying: Common Stock · 3,042 shares Expires 2024-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 04, 2020 Filed Nov 5, 2020 16:46 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionStock Options (Right to Buy) · Derivative | 3,205 | $0.00 Strike: $109.34 | $0.00 |
DisclosureSEC source: 0001127602-20-028214 · form4.xml · derivative · entry 9 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,409 Underlying: Common Stock · 3,205 shares Expires 2023-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 04, 2020 Filed Nov 5, 2020 16:46 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionStock Options (Right to Buy) · Derivative | 492 | $0.00 Strike: $88.05 | $0.00 |
DisclosureSEC source: 0001127602-20-028214 · form4.xml · derivative · entry 8 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,493 Underlying: Common Stock · 492 shares Expires 2022-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.